Products for Research Use Only

BI-3406

CAT: 0804-HY-125817-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-125817-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BI-3406 (compound I-6) is an orally active, highly potent and selective inhibitor of the interaction between KRAS and Son of Sevenless 1 (SOS1) with an IC50 of 6 nM. BI-3406 potently reduces the formation of GTP-loaded KRAS, and inhibits MAPK pathway signaling. BI-3406 has anticancer activity[1][2].
CAS Number
2230836-55-0
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
P38 MAPK; Ras; SOS1
Type
Reference compound
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sos1-in-2.html
Concentration
10mM
Purity
99.95
Solubility
DMSO : 100 mg/mL (ultrasonic) |Ethanol : 100 mg/mL (ultrasonic)
Smiles
CC1=NC(N[C@@H](C2=CC(C(F)(F)F)=CC(N)=C2)C)=C3C=C(O[C@@H]4COCC4)C(OC)=CC3=N1
Molecular Formula
C23H25F3N4O3
Molecular Weight
462.46
Precautions
H302, H312, H332
References & Citations
[1]Michael Gmachl, et al. Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors. WO2018115380A1.|[2]Marco H Hofmann, et al. Abstract PL06-01: Discovery of BI-3406: A potent and selective SOS1::KRAS inhibitor opens a new approach for treating KRAS-driven tumors. December 2019.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
K-Ras